KRAS and cancer: In terms of histone deacetylation modification, Liu et al. fused dCas9 to HDAC1 and achieved deacetylation of histones at the KRAS promoter and effectively silenced the oncogene KRAS, providing a novel approach for cancer therapy (Liu et al., 2021).